These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29682740)

  • 21. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
    Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer screening rates in individuals with different life expectancies.
    Royce TJ; Hendrix LH; Stokes WA; Allen IM; Chen RC
    JAMA Intern Med; 2014 Oct; 174(10):1558-65. PubMed ID: 25133746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers for Compliance to Breast, Colorectal, and Cervical Screening Cancer Tests among Hispanic Patients.
    Miranda-Diaz C; Betancourt E; Ruiz-Candelaria Y; Hunter-Mellado RF
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010021. PubMed ID: 26703676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium Cohort.
    Miglioretti DL; Abraham L; Sprague BL; Lee CI; Bissell MCS; Ho TH; Bowles EJA; Henderson LM; Hubbard RA; Tosteson ANA; Kerlikowske K
    Ann Intern Med; 2024 Oct; 177(10):1297-1307. PubMed ID: 39222505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices.
    Ruffin MT; Gorenflo DW; Woodman B
    J Am Board Fam Pract; 2000; 13(1):1-10. PubMed ID: 10682879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.
    Hofvind S; Sagstad S; Sebuødegård S; Chen Y; Roman M; Lee CI
    Radiology; 2018 Apr; 287(1):58-67. PubMed ID: 29239711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations in breast and colon cancer screening behavior in women.
    Carlos RC; Fendrick AM; Patterson SK; Bernstein SJ
    Acad Radiol; 2005 Apr; 12(4):451-8. PubMed ID: 15831418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.
    Palsdottir T; Nordstrom T; Karlsson A; Grönberg H; Clements M; Eklund M
    BMJ Open; 2019 Mar; 9(3):e027958. PubMed ID: 30928965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. False-positive screening results in the Finnish prostate cancer screening trial.
    Kilpeläinen TP; Tammela TL; Määttänen L; Kujala P; Stenman UH; Ala-Opas M; Murtola TJ; Auvinen A
    Br J Cancer; 2010 Feb; 102(3):469-74. PubMed ID: 20051951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Colorectal Cancer Screening Participation in Southern Khorasan (Iran).
    Ramazani AA; Norozi E; AmirabadiZadeh H; Ehteshampour AR; Salehiniya H
    J Gastrointest Cancer; 2021 Mar; 52(1):187-191. PubMed ID: 32125621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening.
    Hubbard RA; Johnson E; Hsia R; Rutter CM
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1612-9. PubMed ID: 23868091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the acceptance of immunochemical faecal occult blood test and colonoscopy in colorectal cancer screening: a prospective study among Chinese.
    Wong MC; Tsoi KK; Ng SS; Lou VW; Choi SY; Ling KW; Chan FK; Griffiths SM; Sung JJ
    Aliment Pharmacol Ther; 2010 Jul; 32(1):74-82. PubMed ID: 20345501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States.
    Shete S; Deng Y; Shannon J; Faseru B; Middleton D; Iachan R; Bernardo B; Balkrishnan R; Kim SJ; Huang B; Millar MM; Fuemmler B; Jensen JD; Mendoza JA; Hu J; Lazovich D; Robertson L; Demark-Wahnefried W; Paskett ED;
    JAMA Netw Open; 2021 Oct; 4(10):e2128000. PubMed ID: 34605915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data.
    Nelson HD; O'Meara ES; Kerlikowske K; Balch S; Miglioretti D
    Ann Intern Med; 2016 Feb; 164(4):226-35. PubMed ID: 26756902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
    J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of cancer screening: how important is the preventive health examination?
    Fenton JJ; Cai Y; Weiss NS; Elmore JG; Pardee RE; Reid RJ; Baldwin LM
    Arch Intern Med; 2007 Mar; 167(6):580-5. PubMed ID: 17389289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.